IL17A and cancer: We observed that the proportion and relative cell numbers of CD4+IL-17+ subset dramatically went up at the early stage and reached a peak at the middle cancer stage, and then significantly dropped down at the late stage of tumor progression in both 4T1 (Figure 2A and 2B) and E0771 tumor models (Figure 2C and 2D).